Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products

Executive Summary

Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.

You may also be interested in...



PhRMA Played Supporting Role In Case Questioning DTC Advertising In Product Liability Disputes

Association presented oral argument before the Washington State Supreme Court, which certified that drug manufacturers who advertise directly to consumers are not prohibited from using the learned intermediary doctrine as a defense to claims of inadequate warning of a product’s risks.

Pitching Drugs To Physicians: Disclosing Limitations Of Clinical Data May Be Beneficial

US FDA study finds that sales aids for oncology drugs that disclose a study’s data limitations and clinical uncertainty can lead to more appropriate assessments of the data by physicians but does not affect their overall perceptions of a drug’s benefits.

US FDA’s Rx Drug Promo Study Answers $798,000 Question

Viewers spend more time on print ads that have more lengthy important safety information or a brief summary but impact on understanding is unclear, OPDP study finds. Another study finds exaggerated images of drug benefits in TV ads unsurprisingly can mislead consumers.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS120887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel